These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36986664)

  • 41. Development of Itraconazole Tablets Containing Viscous KinetiSol Solid Dispersions: In Vitro and In Vivo Analysis in Dogs.
    Keen JM; LaFountaine JS; Hughey JR; Miller DA; McGinity JW
    AAPS PharmSciTech; 2018 Jul; 19(5):1998-2008. PubMed ID: 29192405
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hot-melt extrusion for enhanced delivery of drug particles.
    Miller DA; McConville JT; Yang W; Williams RO; McGinity JW
    J Pharm Sci; 2007 Feb; 96(2):361-76. PubMed ID: 17075869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preparation and characterisation of Kolliphor® P 188 and P 237 solid dispersion oral tablets containing the poorly water soluble drug disulfiram.
    Ramadhani N; Shabir M; McConville C
    Int J Pharm; 2014 Nov; 475(1-2):514-22. PubMed ID: 25218186
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dissolution performance of binary amorphous drug combinations--Impact of a second drug on the maximum achievable supersaturation.
    Trasi NS; Taylor LS
    Int J Pharm; 2015 Dec; 496(2):282-90. PubMed ID: 26456250
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
    Sun DD; Ju TC; Lee PI
    Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
    Indulkar AS; Lou X; Zhang GGZ; Taylor LS
    Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Absorptive Dissolution Testing: An Improved Approach to Study the Impact of Residual Crystallinity on the Performance of Amorphous Formulations.
    Hate SS; Reutzel-Edens SM; Taylor LS
    J Pharm Sci; 2020 Mar; 109(3):1312-1323. PubMed ID: 31765652
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preparation, characterization and in vitro evaluation of tablets containing microwave-assisted solid dispersions of apremilast.
    Madan JR; Pawar AR; Patil RB; Awasthi R; Dua K
    Polim Med; 2018; 48(1):17-24. PubMed ID: 30657654
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of controlled release amorphous solid dispersions (CRASD) using polyvinyl acetate-based release retarding materials: Effect of dosage form design.
    Lugtu-Pe JA; Ghaffari A; Chen K; Kane A; Wu XY
    Eur J Pharm Sci; 2018 Nov; 124():319-327. PubMed ID: 30194980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Surface area normalized dissolution to study differences in itraconazole-copovidone solid dispersions prepared by spray-drying and hot melt extrusion.
    Bhardwaj V; Trasi NS; Zemlyanov DY; Taylor LS
    Int J Pharm; 2018 Apr; 540(1-2):106-119. PubMed ID: 29425762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Downstream processing of a ternary amorphous solid dispersion: The impacts of spray drying and hot melt extrusion on powder flow, compression and dissolution.
    Davis MT; Potter CB; Walker GM
    Int J Pharm; 2018 Jun; 544(1):242-253. PubMed ID: 29689366
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insights into the Release Mechanisms of ITZ:HPMCAS Amorphous Solid Dispersions: The Role of Drug-Rich Colloids.
    Nunes PD; Pinto JF; Henriques J; Paiva AM
    Mol Pharm; 2022 Jan; 19(1):51-66. PubMed ID: 34919407
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of immediate release 3D-printed dosage forms for a poorly water-soluble drug by fused deposition modeling: Study of morphology, solid state and dissolution.
    Fanous M; Bitar M; Gold S; Sobczuk A; Hirsch S; Ogorka J; Imanidis G
    Int J Pharm; 2021 Apr; 599():120417. PubMed ID: 33647418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surface Characterization as a Tool for Identifying the Factors Affecting the Dissolution Rate of Amorphous Solid Dispersion Tablets.
    Yu D; Fiddler F; Ibrahim A; Sanedrin R; Tremblay H; Hoag SW
    AAPS PharmSciTech; 2022 Oct; 23(8):282. PubMed ID: 36253562
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Formulation of fast disintegrating tablets of ternary solid dispersions consisting of TPGS 1000 and HPMC 2910 or PVPVA 64 to improve the dissolution of the anti-HIV drug UC 781.
    Goddeeris C; Willems T; Van den Mooter G
    Eur J Pharm Sci; 2008 Aug; 34(4-5):293-302. PubMed ID: 18602800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigation of a suitable in vitro dissolution test for itraconazole-based solid dispersions.
    Thiry J; Broze G; Pestieau A; Tatton AS; Baumans F; Damblon C; Krier F; Evrard B
    Eur J Pharm Sci; 2016 Mar; 85():94-105. PubMed ID: 26850682
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physical stability and solubility of the thermotropic mesophase of fenoprofen calcium as pure drug and in a tablet formulation.
    Patterson J; Bary A; Rades T
    Int J Pharm; 2002 Oct; 247(1-2):147-57. PubMed ID: 12429493
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation.
    Surampalli G; Nanjwade BK; Patil PA; Chilla R
    Drug Deliv; 2016 Sep; 23(7):2124-2138. PubMed ID: 25080228
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined Effects of Supersaturation Rates and Doses on the Kinetic-Solubility Profiles of Amorphous Solid Dispersions Based on Water-Insoluble Poly(2-hydroxyethyl methacrylate) Hydrogels.
    Schver GCRM; Lee PI
    Mol Pharm; 2018 May; 15(5):2017-2026. PubMed ID: 29601723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Designing robust immediate release tablet formulations avoiding food effects for BCS class 3 drugs.
    Zaheer K; Langguth P
    Eur J Pharm Biopharm; 2019 Jun; 139():177-185. PubMed ID: 30902732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.